Last reviewed · How we verify
Placebo to MK-0954A
MK-0954A is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.
MK-0954A is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chemotherapy-induced nausea and vomiting (CINV).
At a glance
| Generic name | Placebo to MK-0954A |
|---|---|
| Sponsor | Organon and Co |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
NK1 receptor antagonists work by blocking the binding of substance P, a neuropeptide involved in pain transmission and emesis pathways. By inhibiting NK1 receptors, MK-0954A may reduce nausea, vomiting, and potentially pain signaling. This mechanism has been explored for chemotherapy-induced nausea and vomiting (CINV) and other conditions involving substance P dysregulation.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
Common side effects
- Headache
- Fatigue
- Constipation
- Dizziness
Key clinical trials
- A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327) (PHASE3)
- MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352) (PHASE3)
- A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351) (PHASE3)
- Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to MK-0954A CI brief — competitive landscape report
- Placebo to MK-0954A updates RSS · CI watch RSS
- Organon and Co portfolio CI